ArticleNature medicine2023
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.
Abstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- T cell immunity in glioma and potential implications for immunotherapy: A systematic review.Neuro-oncology · 2026Pooled it
- Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trial.Neuro-oncology · 2024Trial
- Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma.Neuro-oncology · 2026Article
- Integrating Radiogenomics and CSF-Based Liquid Biopsy Sequencing for Precision Neuro-Oncology.International journal of molecular sciences · 2026Review
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- NT-I7, a Long-Acting Interleukin 7, Increases Lymphocyte Counts and Induces CD8+ T-cell Clonotype Expansion in Patients with Newly Diagnosed High-Grade Gliomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Applications of transcranial focused ultrasound for primary brain tumors.Neuro-oncology advances · 2026Review
- Laser interstitial thermal therapy versus stereotactic radiosurgery for first-time treatment of recurrent glioblastoma: a retrospective single-center study.Journal of neuro-oncology · 2026Article
- A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma.Neuro-oncology · 2026Article
- p53 Pathway-Targeted Therapeutic Strategies in Glioblastoma: A CNS-Specific Framework Integrating Therapeutic Resistance, Molecular Stratification, CNS Pharmacology, and Clinical Translation.Drug design, development and therapy · 2026Review
- Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.Neuro-oncology · 2025Review
- Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses.Science translational medicine · 2025Article
- Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial.Nature medicine · 2025Article
- Glioma drug development benefits from emerging phase 0 and window-of-opportunity trial paradigm.Cell communication and signaling : CCS · 2025Review
- A hitchhiker's guide to cerebrospinal fluid biomarkers for neuro-oncology.Neuro-oncology · 2025Review
- Gabapentinoids confer survival benefit in human glioblastoma.Nature communications · 2025Article
- Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: A report of the RANO resect group.Neuro-oncology · 2025Article
- A field resource for the glioma cerebrospinal fluid proteome: Impacts of resection and location on biomarker discovery.Neuro-oncology · 2025Article
- Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.Nature medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Kirit SinghThe Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-0419-5381
Kelly M HotchkissThe Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
Ian F ParneyMayo Clinic, Rochester, MN, USA.ORCID 0000-0002-9702-8047
John De GrootDivision of Neuro-Oncology, Department of Neurological Surgery, University of California San Francisco (UCSF), San Francisco, CA, USA.
Solmaz SahebjamNational Institute of Health, Bethesda, MD, USA.ORCID 0000-0001-9930-9937
Nader SanaiIvy Brain Tumor Center, The Barrow Neurological Institute, Phoenix, AZ, USA.ORCID 0000-0002-5581-0516
Michael PlattenMedical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.ORCID 0000-0002-4746-887X
Evanthia GalanisMayo Clinic, Rochester, MN, USA.
Michael LimDepartment of Neurosurgery, Stanford University, School of Medicine, Stanford, CA, USA.ORCID 0000-0003-0523-3076
Patrick Y WenCenter for Neuro-Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Giuseppe MinnitiDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy.
Howard ColmanHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Timothy F CloughesyNeuro-Oncology Program, University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0002-8656-7483
Minesh P MehtaMiami Cancer Institute, Miami, FL, USA.
Marjolein GeurtsErasmus MC Cancer Institute, Rotterdam, The Netherlands.
Isabel Arrillaga-RomanyMassachusetts General Hospital, Boston, MA, USA.
Annick DesjardinsThe Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0003-3869-8283
Kirk TannerNational Brain Tumor Society (NBTS), Newton, MA, USA.
Susan ShortSchool of Medicine, University of Leeds, Leeds, UK.ORCID 0000-0003-4423-7256
David AronsNational Brain Tumor Society (NBTS), Newton, MA, USA.
Elizabeth DukeUS Food and Drug Administration, Silver Spring, MD, USA.
Wolfgang WickGerman Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID 0000-0002-6171-634X
Stephen J BagleyPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-7117-0539
David M AshleyThe Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
Priya KumthekarFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Roel VerhaakSchool of Medicine, Yale University, New Haven, CT, USA.ORCID 0000-0003-2773-0436
Anthony J ChalmersSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-1746-7278
Anoop P PatelThe Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
Colin WattsInstitute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0003-3531-8791
Peter E FecciSurgical Neuro-Oncology, Department of Neurology, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-2912-8695
Tracy T BatchelorBrigham and Women's Hospital, Boston, MA, US.
Michael WellerDepartment of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-1748-174X
Michael A VogelbaumDepartment of NeuroOncology, H. Lee Moffit Cancer Center and Research Institute, Tampa, FL, USA.
Matthias PreusserDepartment of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-3541-2315
Mitchel S BergerDepartment of Neurological Surgery, UCSF Brain Tumor Center, San Francisco, CA, USA.
Mustafa KhasrawThe Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA. mustafa.khasraw@duke.edu.ORCID 0000-0003-3249-9849
Funding
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MViral Oncology Training GrantT32CA009111 · NCI · DUKE UNIVERSITY · PI LUFTIG, MICAH A. · 1985 to 2023
$8.9MCancer Research UK 11423Cancer Research UK 17870Cancer Research UK 20546Cancer Research UK 20747Cancer Research UK 28803Cancer Research UK 28832Medical Research Council G0802755Medical Research Council G108/589NCI NIH HHS P50 CA211015NCI NIH HHS T32 CA009111
Abstract
PubMed holds no abstract for this paper.
Indexed as
Brain NeoplasmsGlioblastomaDrug DevelopmentHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.